This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:celiac [03.13.2019] – [recent research] sallieq | home:diseases:celiac [07.19.2019] – [Epidemiology] sallieq | ||
---|---|---|---|
Line 5: | Line 5: | ||
====== Celiac disease ====== | ====== Celiac disease ====== | ||
- | < | + | < |
Line 31: | Line 31: | ||
CONCLUSIONS: | CONCLUSIONS: | ||
</ | </ | ||
+ | |||
+ | The emerging data on viral and bacterial microbe-host interactions and their alterations in celiac disease provides a plausible mechanism linking environmental risk and disease development. (({{pubmed> | ||
Line 66: | Line 68: | ||
Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | ||
- | In a methotrexate-induced model of intestinal mucositis, olmesartan reduced inflammation | + | In 2015 I read that 6 individuals in the USA are currently suing maker of Benicar. Somewhere I saw that 1.9 million individuals are currently taking Olmesartan Medoxomil. |
+ | |||
+ | 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor | ||
+ | (({{pubmed> | ||
{{tag> | {{tag> |